Article citationsMore>>

Thorlund, K., Mills, E.J., Wu, P., Ramos, E., Chatterjee, A., Druyts, E., et al. (2014) Comparative Efficacy of Triptans for the Abortive Treatment of Migraine: A Multiple Treatment Comparison Meta-Analysis. Cephalalgia: An International Journal of Headache, 34, 258-267.
https://doi.org/10.1177/0333102413508661

has been cited by the following article:

• TITLE: A Combination of Tanacetum parthenium, Griffonia simplicifolia and Magnesium (Aurastop) as Symptomatic Acute Treatment for Migraine Aura: A Retrospective Cohort Study

  AUTHORS: Paola Zavarise, Giorgio Dalla Volta

  KEYWORDS: Migraine Aura, Cortical Spreading Depression, NMDA Receptor

  JOURNAL NAME: Open Access Library Journal, Vol.4 No.6, June 8, 2017

  ABSTRACT: Background: effective treatments for migraine aura and related symptoms are not yet well established. In the last years, several herbal and/or nutraceutical preparations have been proposed as potential treatment. We report the results of a retrospective analysis on the synergistic effect of three nutraceutical components (Tanacetum parthenium, Griffonia simpliciofila and Magnesium, Aurastop) as symptomatic treatment of migraine aura and related symptoms. Method: Forty-nine subjects with headache with aura were recruited from the headache Center of the Istituto Clinico Citta’ di Brescia to enter the studied that consist to treat the first 3 aura attacks as usual and the next 3 taking a tablet of Aurastop at the beginning of the aura phenomena. They had to describe aura and headache characteristics of previous three attacks (t1) and the modification of these parameters with the assumption of Aurastop for the following three attacks (t2). Results: A significant reduction (>50%) in aura duration (t1 = 33.6 ± 10.1 minutes vs. t2 = 9.4 ± 6.2 minutes, p Tanacetum parthenium, Griffonia simpliciofila and Magnesium (Aurastop) highlights the idea that symptomatic treatment potentially modulating cortical spreading depression could deserve attention to mitigate aura and related symptoms (migraine as well as long-lasting discomfort). Further blinded, placebo-controlled studies on larger groups are warranted.